WallStSmart
INDP

Indaptus Therapeutics Inc

NASDAQ: INDP · HEALTHCARE · BIOTECHNOLOGY

$3.45
+8.83% today

Updated 2026-11-16

Market cap
$439.70M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-6.15
Dividend yield
—
52W range
$1 – $6
Volume
0.8M

WallStSmart proprietary scores

17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
3.5
Quality
D
3.0
Profitability
D
5.0
Valuation
C+
1/9
Piotroski F-Score
Weak
-18.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →253 stocks currently score above 75

Price targets

Analyst target
$10.00
+189.86%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -18.54 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-1.44M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00—
Net income$-14.32M$-15.42M$-15.02M$-20.85M$-1.05M
EPS————$-6.15
Free cash flow$-13.25M$-13.41M$-12.32M$-14.82M$-1.44M
Profit margin—————

Recent insider activity

DateInsiderTypeSharesPrice
2026-03-23LAZAR, DAVID E.Sale700,000—
2026-03-23LAZAR, DAVID E.Sale196,800—
2026-02-26JABBOUR, JEROME DBuy25,000—

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
INDP$439.70M174.33.05.03.5—Avoid
LLY$1.27T749.310.05.06.0—Strong Buy
JNJ$682.52B544.78.53.75.5—Buy
ABBV$520.47B776.79.04.05.0-87.62%Strong Buy
UNH$363.01B626.76.04.75.5-24.67%Buy
MRK$362.27B423.36.52.05.0-73.98%Hold

Smart narrative

Indaptus Therapeutics Inc trades at $3.45. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -18.54, it sits in the distress.

Frequently asked questions

What is Indaptus Therapeutics Inc's stock price?

Indaptus Therapeutics Inc (INDP) trades at $3.45.

Is Indaptus Therapeutics Inc overvalued?

Indaptus Therapeutics Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Indaptus Therapeutics Inc (INDP)?

The 12-month analyst consensus target is $10.00, about 189.9% above the current $3.45. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Indaptus Therapeutics Inc's Altman Z-Score is -18.54, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio—
ROE-135.62%
Beta0.94
50D MA$2.63
200D MA$2.29
Shares out0.13B
Float0.04B
Short ratio—
Avg volume0.8M

Performance

1 week-4.52%
1 month+11.23%
3 months+196.26%
YTD+8.93%
1 year+26.29%
3 years—
5 years—